Remdesivir Compulsory Licensing Is A Dead End For Europe
Possibility Had Been Mooted After US Struck Deal For Gilead Supply
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”